355 related articles for article (PubMed ID: 18266400)
21. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study.
Silverman SL; Watts NB; Delmas PD; Lange JL; Lindsay R
Osteoporos Int; 2007 Jan; 18(1):25-34. PubMed ID: 17106785
[TBL] [Abstract][Full Text] [Related]
22. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
Liberman UA; Weiss SR; Bröll J; Minne HW; Quan H; Bell NH; Rodriguez-Portales J; Downs RW; Dequeker J; Favus M
N Engl J Med; 1995 Nov; 333(22):1437-43. PubMed ID: 7477143
[TBL] [Abstract][Full Text] [Related]
23. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
Reid DM; Devogelaer JP; Saag K; Roux C; Lau CS; Reginster JY; Papanastasiou P; Ferreira A; Hartl F; Fashola T; Mesenbrink P; Sambrook PN;
Lancet; 2009 Apr; 373(9671):1253-63. PubMed ID: 19362675
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy.
Lindsay R; Watts NB; Lange JL; Delmas PD; Silverman SL
Osteoporos Int; 2013 Aug; 24(8):2345-52. PubMed ID: 23612793
[TBL] [Abstract][Full Text] [Related]
25. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
Lems WF; Lodder MC; Lips P; Bijlsma JW; Geusens P; Schrameijer N; van de Ven CM; Dijkmans BA
Osteoporos Int; 2006; 17(5):716-23. PubMed ID: 16463007
[TBL] [Abstract][Full Text] [Related]
26. Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study.
Ringe JD; Farahmand P; Faber H; Dorst A
Rheumatol Int; 2009 Jan; 29(3):311-5. PubMed ID: 18762944
[TBL] [Abstract][Full Text] [Related]
27. Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study.
Matsumoto T; Hagino H; Shiraki M; Fukunaga M; Nakano T; Takaoka K; Morii H; Ohashi Y; Nakamura T
Osteoporos Int; 2009 Aug; 20(8):1429-37. PubMed ID: 19101754
[TBL] [Abstract][Full Text] [Related]
28. Effects of once-monthly minodronate versus risedronate in osteoporosis patients with rheumatoid arthritis: a 12-month randomized head-to-head comparison.
Kumagai K; Harigane K; Kusayama Y; Tezuka T; Choe H; Inaba Y; Saito T
Osteoporos Int; 2018 Jul; 29(7):1637-1642. PubMed ID: 29574518
[TBL] [Abstract][Full Text] [Related]
29. Potential excessive suppression of bone turnover with long-term oral bisphosphonate therapy in postmenopausal osteoporotic patients.
Iizuka T; Matsukawa M
Climacteric; 2008 Aug; 11(4):287-95. PubMed ID: 18645694
[TBL] [Abstract][Full Text] [Related]
30. Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate.
Iwamoto J; Takeda T; Sato Y
Expert Opin Pharmacother; 2007 Nov; 8(16):2743-56. PubMed ID: 17956196
[TBL] [Abstract][Full Text] [Related]
31. Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA.
Eisman JA; Cortet B; Boolell M; Ionescu-Ittu R; Vekeman F; Heroux J; Thomasius F
Osteoporos Int; 2023 May; 34(5):977-991. PubMed ID: 36872338
[TBL] [Abstract][Full Text] [Related]
32. Unusual mid-shaft fractures during long-term bisphosphonate therapy.
Odvina CV; Levy S; Rao S; Zerwekh JE; Rao DS
Clin Endocrinol (Oxf); 2010 Feb; 72(2):161-8. PubMed ID: 19302584
[TBL] [Abstract][Full Text] [Related]
33. Anti-fracture efficacy of risedronic acid in men: A meta-analysis of randomized controlled trials.
Zhong ZM; Chen JT
Clin Drug Investig; 2009; 29(5):349-57. PubMed ID: 19366276
[TBL] [Abstract][Full Text] [Related]
34. What is the optimal duration of bisphosphonate therapy?
Ott SM
Cleve Clin J Med; 2011 Sep; 78(9):619-30. PubMed ID: 21885695
[TBL] [Abstract][Full Text] [Related]
35. Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5mg once-daily dosage regimen.
Hagino H; Kishimoto H; Ohishi H; Horii S; Nakamura T
Bone; 2014 Feb; 59():44-52. PubMed ID: 24184313
[TBL] [Abstract][Full Text] [Related]
36. Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.
Cadarette SM; Katz JN; Brookhart MA; Stürmer T; Stedman MR; Solomon DH
Ann Intern Med; 2008 May; 148(9):637-46. PubMed ID: 18458276
[TBL] [Abstract][Full Text] [Related]
37. The effects of teriparatide and bisphosphonates on new fractures in postmenopausal women with osteoporosis: A protocol for systematic review and meta-analysis.
Ouyang Y; Chen S; Wan T; Zheng G; Sun G
Medicine (Baltimore); 2021 Feb; 100(7):e24839. PubMed ID: 33607854
[TBL] [Abstract][Full Text] [Related]
38. Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
Martin KE; Yu J; Campbell HE; Abarca J; White TJ
J Manag Care Pharm; 2011 Oct; 17(8):596-609. PubMed ID: 21942301
[TBL] [Abstract][Full Text] [Related]
39. Fracture risk remains reduced one year after discontinuation of risedronate.
Watts NB; Chines A; Olszynski WP; McKeever CD; McClung MR; Zhou X; Grauer A
Osteoporos Int; 2008 Mar; 19(3):365-72. PubMed ID: 17938986
[TBL] [Abstract][Full Text] [Related]
40. Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates.
Hochberg MC
Curr Osteoporos Rep; 2008 Sep; 6(3):89-94. PubMed ID: 18752769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]